Activation of KLB/FGFR1c by native or synthetic FGF21 molecules has been shown to induce body weight loss and reduce circulating triglyceride levels in rodent models of obesity, non-human primates and humans [1, 3–6]. Here, FGF21 is linked to obesity disorder.